Maciej Stanczyk
Memorial Hospital of South Bend
9 Papers
19 Citations
Maciej Stanczyk is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Nanocarriers & Conjugate. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Monika Marcinkowska,Maciej Stanczyk,Anna Janaszewska,Ewelina Sobierajska,Arkadiusz Chworos,Barbara Klajnert-Maculewicz,Barbara Klajnert-Maculewicz +6 more
TL;DR: Two PAMAM dendrimer-trastuzumab conjugates that carried docetaxel or paclitaxel, specifically targeted to cells which overexpressed HER-2 are developed and synthesised to demonstrate the utility of trastuzuab as a targeting agent and present an promising approach for the improvement of efficacy of targeted delivery of anticancer drugs.
Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody-Trastuzumab: The New Approach of a Well-Known Strategy.
Monika Marcinkowska,Ewelina Sobierajska,Maciej Stanczyk,Anna Janaszewska,Arkadiusz Chworos,Barbara Klajnert-Maculewicz,Barbara Klajnert-Maculewicz +6 more
TL;DR: Results reveal that trastuzumab can be used as a targeting agent in PAMAM–dox–trastzumab conjugate, which could lead to improvements in the effectiveness of drug delivery systems for tumors that overexpress HER-2.
51
Sugar Modification Enhances Cytotoxic Activity of PAMAM-Doxorubicin Conjugate in Glucose-Deprived MCF-7 Cells - Possible Role of GLUT1 Transporter.
Krzysztof Sztandera,Paula Działak,Monika Marcinkowska,Maciej Stanczyk,Michał Gorzkiewicz,Anna Janaszewska,Barbara Klajnert-Maculewicz,Barbara Klajnert-Maculewicz +7 more
TL;DR: The results suggest that PAMAM-glucose formulations may constitute an efficient platform for the specific delivery of anticancer drugs to tumor cells overexpressing transporters of GLUT family.
Unusual Enhancement of Doxorubicin Activity on Co-Delivery with Polyhedral Oligomeric Silsesquioxane (POSS)
Ewelina Sobierajska,Malgorzata Konopka,Anna Janaszewska,Kinga Piorecka,Andrzej Błauż,Barbara Klajnert-Maculewicz,Barbara Klajnert-Maculewicz,Maciej Stanczyk,Wlodzimierz A. Stanczyk +8 more
TL;DR: It can be claimed that the polyhedral oligomeric silsesquioxane (T8-POSS) is a promising, complex nanocarrier for doxorubicin delivery.
12
[Trastuzumab - a monoclonal antibody - and dendrimers in a targeted therapy for breast cancer].
TL;DR: An overview of publications about the use of trastuzumab in in vitro, in vivo and clinical studies, as well as the latest developments of biology and chemistry, whose goal is to create the perfect, targeted carrier are presented.
8